Lexington, Ky. - US Equestrian is pleased to announce that it will continue its longstanding partnership with American Regent Animal Health, makers of Adequan i.m.® (polysulfated glycosaminogylcan).
Adequan i.m. will continue as the Official Joint Therapy Product of US Equestrian and an Official Supplier of US Equestrian Teams. In addition, Adequan i.m. will remain the title sponsor of the Adequan®/USEF Para Dressage National Championship, the Adequan®/USEF Young Adult Brentina Cup Championship, and the Adequan®/USEF Junior Dressage National Championship, held at the 2025 U.S. Dressage Festival of Champions. Adequan i.m. will also return as the title sponsor of the Adequan®/USEF Junior Hunter National Championship.
The U.S. Dressage Festival of Champions showcases top athletes and horses across 17 divisions, ranging from Young Horse to Grand Prix. The 2025 U.S. Dressage Festival of Champions will be held August 18-24, at HITS Chicago Lamplight Equestrian Center in Wayne, Ill.
The Adequan®/USEF Junior Hunter National Championship features more than 2,000 qualified hunters across the 3’3” and 3’6” heights. This year’s East Coast championship will be held June 18-22, at the Kentucky Horse Park in Lexington, Ky and the West Coast championship will be held July 24-27 at HITS Del Mar Horse Park in Del Mar, Ca.
Adequan i.m. will also continue as the title sponsor of the Adequan®/USEF Para Dressage Athlete of Honor Award Program. This program recognizes the highest-ranked para dressage athletes competing in the FEI Novice A & B Tests, supporting athletes that are on their way to future success in international para dressage competitions. The program is considered a steppingstone to the USEF Para Dressage Program Pathway. This year’s presentation will take place at the 2025 U.S. Dressage Festival of Champions.
“We are thrilled to continue our long-standing partnership with Adequan i.m.,” said US Equestrian CEO Bill Moroney. “Their unwavering support of developing athletes is crucial in helping nurture the future of our sport. With Adequan’s continued commitment, we are able to provide educational competition experience for our young athletes and horses as they pursue their dreams of excellence.”
“We’re proud to continue our partnership with USEF and underscore our support for Para Dressage athletes. Each year is an opportunity to champion the sport, strengthen the bond between horse and rider, and help keep them moving forward together,” said Marjorie Lathrop, Marketing Director at American Regent Animal Health.
Adequan i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
Adequan i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. WARNING: Not for use in humans. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. See full Prescribing information at adequan.com.
About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for over three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified American Regent portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
PP-AI-US-1263